Microbiology

  1. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

    1. Philip J.M. Brouwer
    2. Tom G. Caniels
    3. Karlijn van der Straten
    4. Jonne L. Snitselaar
    5. Yoann Aldon
    6. Sandhya Bangaru
    7. Jonathan L. Torres
    8. Nisreen M.A. Okba
    9. Mathieu Claireaux
    10. Gius Kerster
    11. Arthur E.H. Bentlage
    12. Marlies M. van Haaren
    13. Denise Guerra
    14. Judith A. Burger
    15. Edith E. Schermer
    16. Kirsten D. Verheul
    17. Niels van der Velde
    18. Alex van der Kooi
    19. Jelle van Schooten
    20. Mariëlle J. van Breemen
    21. Tom P. L. Bijl
    22. Kwinten Sliepen
    23. Aafke Aartse
    24. Ronald Derking
    25. Ilja Bontjer
    26. Neeltje A. Kootstra
    27. W. Joost Wiersinga
    28. Gestur Vidarsson
    29. Bart L. Haagmans
    30. Andrew B. Ward
    31. Godelieve J. de Bree
    32. Rogier W. Sanders
    33. Marit J. van Gils

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  2. Potential antiviral options against SARS-CoV-2 infection

    1. Aleksandr Ianevski
    2. Rouan Yao
    3. Mona Høysæter Fenstad
    4. Svetlana Biza
    5. Eva Zusinaite
    6. Tuuli Reisberg
    7. Hilde Lysvand
    8. Kirsti Løseth
    9. Veslemøy Malm Landsem
    10. Janne Fossum Malmring
    11. Valentyn Oksenych
    12. Sten Even Erlandsen
    13. Per Arne Aas
    14. Lars Hagen
    15. Caroline H. Pettersen
    16. Tanel Tenson
    17. Jan Egil Afset
    18. Svein Arne Nordbø
    19. Magnar Bjørås
    20. Denis E. Kainov

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  3. Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution

    1. Atreyee Basu
    2. Tatyana Zinger
    3. Kenneth Inglima
    4. Kar-mun Woo
    5. Onome Atie
    6. Lauren Yurasits
    7. Benjamin See
    8. Maria E. Aguero-Rosenfeld

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  4. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate

    1. Meehyun Ko
    2. Sangeun Jeon
    3. Wang-Shick Ryu
    4. Seungtaek Kim

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  5. Clinical performance of SARS-CoV-2 IgG antibody tests and potential protective immunity

    1. Niko Kohmer
    2. Sandra Westhaus
    3. Cornelia Rühl
    4. Sandra Ciesek
    5. Holger F. Rabenau

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  6. Multiple introductions, regional spread and local differentiation during the first week of COVID-19 epidemic in Montevideo, Uruguay

    1. Cecilia Salazar
    2. Florencia Díaz-Viraqué
    3. Marianoel Pereira-Gómez
    4. Ignacio Ferrés
    5. Pilar Moreno
    6. Gonzalo Moratorio
    7. Gregorio Iraola

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  7. SARS-CoV-2 Spike Glycoprotein and ACE2 interaction reveals modulation of viral entry in wild and domestic animals

    1. Manas Ranjan Praharaj
    2. Priyanka Garg
    3. Veerbhan Kesarwani
    4. Neelam A Topno
    5. Raja Ishaq Nabi Khan
    6. Shailesh Sharma
    7. Manjit Panigrahi
    8. B P Mishra
    9. Bina Mishra
    10. G Sai kumar
    11. Ravi Kumar Gandham
    12. Raj Kumar Singh
    13. Subeer Majumdar
    14. Trilochan Mohapatra

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  8. Efficacy of a novel iodine complex solution, CupriDyne, in inactivating SARS-CoV-2

    1. Emily Mantlo
    2. Alex Evans
    3. Laura Patterson-Fortin
    4. Jenny Boutros
    5. Richard Smith
    6. Slobodan Paessler

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  9. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle

    1. Clarisse Salgado Benvindo da Silva
    2. Melissa Thaler
    3. Ali Tas
    4. Natacha S. Ogando
    5. Peter J. Bredenbeek
    6. Dennis K. Ninaber
    7. Ying Wang
    8. Pieter S. Hiemstra
    9. Eric J. Snijder
    10. Martijn J. van Hemert

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity

  10. The coding capacity of SARS-CoV-2

    1. Yaara Finkel
    2. Orel Mizrahi
    3. Aharon Nachshon
    4. Shira Weingarten-Gabbay
    5. David Morgenstern
    6. Yfat Yahalom-Ronen
    7. Hadas Tamir
    8. Hagit Achdout
    9. Dana Stein
    10. Ofir Israeli
    11. Adi Beth-Din
    12. Sharon Melamed
    13. Shay Weiss
    14. Tomer Israely
    15. Nir Paran
    16. Michal Schwartz
    17. Noam Stern-Ginossar

    Reviewed by ScreenIT

    1 evaluationAppears in 1 listLatest version Latest activity
Previous Page 66 of 252 Next